A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.

开始日期2024-12-12

申办/合作机构

上海细胞治疗集团股份有限公司

NCT06446128

/ Active, not recruiting早期临床1期

A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

开始日期2024-04-01

申办/合作机构

上海细胞治疗集团股份有限公司

NCT06327997

/ Recruiting早期临床1期

Exploratory Study on the Treatment of Advanced Solid Tumor With Non-viral Vector Multi-targeted Autosecretory Multifunctional Antibody CAR-T Cell Injection

The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy for advanced solid tumors with positive mesothelin and MUC1.Patients were screened, peripheral blood mononuclear cells (PBMC) were isolated from eligible patients, and cells were prepared. Pretreatment was performed within 5 days before infusion, and CAR T cells were infused on day 0 (the dose was determined according to the requirements of climbing/expansion). The safety intensive observation period was 28 days after infusion, and the clinical efficacy after infusion was evaluated on days 28-34. The follow-up observation and evaluation were carried out according to the follow-up visit point, and the follow-up period was 1 year. From the second year, the telephone follow-up period was entered.

开始日期2024-03-07

申办/合作机构

上海细胞治疗集团股份有限公司

100 项与上海细胞治疗集团股份有限公司相关的临床结果

登录后查看更多信息

0 项与上海细胞治疗集团股份有限公司相关的专利（医药）

登录后查看更多信息

项与上海细胞治疗集团股份有限公司相关的文献（医药）

2025-08-11·Journal of Translational Medicine

Low-liver-accumulation lipid nanoparticles enhance the efficacy and safety of HPV therapeutic tumor vaccines.

Article

作者: Fang, Yuan ; Guo, Chuanxin ; Yang, Shuyan ; Bai, Xuesen ; Wang, Meng ; Zeng, Jianyao ; Liu, Tao ; Wang, Xiaodie ; Qian, Qijun ; Wang, Pei ; Cai, Xiaoru ; Sun, Yan ; Tian, Zhidan

BACKGROUND:

Lipid nanoparticles (LNPs) hold significant potential in vaccine and cancer therapy, but conventional LNPs often cause hepatotoxicity and reduced efficacy due to liver accumulation.

METHODS:

LNP molecules with varying tail lengths were synthesized in vitro. Transfection efficiency was assessed in vitro via flow cytometry. The BALB/c model was used to evaluate in vivo delivery efficiency of the LNPs. The C57BL/6 mouse model was used to evaluate in vivo anti-tumor pharmacodynamics, along with tumor-infiltrating immune cells and serum inflammatory cytokines. The Sprague Dawley (SD) rat model was used for toxicity testing of the candidate LNP.

RESULTS:

Lipid 7 demonstrated threefold higher mRNA expression efficiency at the injection site while minimizing liver retention. In an HPV tumor model, Lipid 7 achieved tumor suppression comparable to SM-102-based LNP but outperformed in remodeling the tumor microenvironment (dendritic cells: 12.1% vs. 5.1%; natural killer cells: 1.1% vs. 0.5%) and elevating serum immune cytokines (TNF-α, IL-1β, etc., 1.2-1.8-fold higher). Critically, Lipid 7 reduced off-target mRNA accumulation in the heart, liver, spleen, lungs, and kidneys, mitigating hepatotoxicity risks associated with traditional LNPs.

CONCLUSIONS:

By employing a novel, non-patented ionizable lipid design, this work balances delivery efficiency and biosafety, Lipid 7 offers a high-efficacy, low-toxicity therapeutic strategy for HPV-related cancers.

2025-01-01·DRUG DISCOVERY TODAY

Targeting spleen tyrosine kinase (SYK): structure, mechanisms and drug discovery

Review

作者: Lu, Yingying ; Wang, Lilin ; Zhang, Lan ; Zhang, Tongtong ; Guo, Chuanxin ; Zhang, Shuangqian

Spleen tyrosine kinase (SYK) is a crucial non-receptor tyrosine kinase involved in signaling pathways that regulate various cellular processes. It is primarily expressed in hematopoietic cells and myeloid cells, which are crucial for B-cell development, maturation and antibody production, and it is a key therapeutic target for autoimmune and allergic diseases. Overexpression of SYK is also associated with cancer and cardiovascular, cerebrovascular and neurodegenerative diseases, contributing to their initiation and progression. SYK is a promising target for drug development, and several inhibitors have already been reported. This review covers the structure and regulatory pathways of SYK, as well as its links to various diseases. It also highlights key small-molecule SYK inhibitors, their design strategies and their potential therapeutic benefits, aiming to enhance our understanding and aid in the discovery of more-effective SYK inhibitors.

2024-10-01·DRUG DISCOVERY TODAY

Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy

Review

作者: Li, Zixiang ; Zhang, Lan ; Wang, Huiping ; Fu, Leilei ; Jin, Wenke ; Guo, Chuanxin

Eukaryotic elongation factor 2 kinase (eEF2K) is a member of the α-kinase family that is activated by calcium/calmodulin. Of note, eEF2K is crucial for regulating translation and is often highly overexpressed in malignant cells. Therefore in this review, we summarize the molecular structure of eEF2K and its oncogenic roles in cancer. Moreover, we further discuss the inhibition of eEF2K with small-molecule inhibitors and other new emerging therapeutic strategies in cancer therapy. Taken together, these inspiring findings provide new insights into a promising strategy for inhibiting eEF2K to greatly improve future cancer therapy.

418

项与上海细胞治疗集团股份有限公司相关的新闻（医药）

2025-08-14

·同写意

易慕峰实体瘤CAR-T发表最新研究成果 | 会员动态

免疫疗法细胞疗法临床1期

2025-08-14

·同写意

瀚枢生物：提供一站式神经系统药物研发解决方案 | 写意会员

临床申请

2025-08-13

·同写意

国产首款，如何成就？

上市批准

100 项与上海细胞治疗集团股份有限公司相关的药物交易

登录后查看更多信息

100 项与上海细胞治疗集团股份有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年08月15日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

早期临床1期

临床2期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

自分泌PD1抗体靶向间皮素嵌合抗原受体T细胞（上海细胞治疗集团） ( MSLN x PD-1 )	间皮瘤更多	临床1/2期
PD-1 antibody CD19-CAR T therapy ( CD19 x PD-1 )	B细胞淋巴瘤更多	临床1/2期
BZE-2204 ( BCMA x CD19 x CD22 )	难治性B细胞淋巴瘤更多	早期临床1期
BaizeDC ( CTLA4 x PD-1 x p53 x survivin )	实体瘤更多	早期临床1期
BZT-2312 ( MSLN x PD-1 )	晚期恶性实体瘤更多	早期临床1期